Baird reiterated an Outperform rating and $221.00 price target on Alexion Pharmaceuticals (NASDAQ: ALXN) following Strensiq's FDA approval for hypophosphatasia ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS Change Analyst EPS View Analyst PT Change

Cowen Remains Bullish Following Alexion Pharma's (ALXN) 3Q October 29, 2015 1:14 PM FDA Approves Strensiq for Alexion Pharma (ALXN); Oppenheimer Reiterates Outperform October 26, 2015 3:25 PM Alexion Pharma (ALXN) to Resume Trading at 4:15 PM ETOctober 23, 2015 3:57 PM FDA Approves Strensiq™ (asfotase alfa) for Treatment of Patients with Perinatal-, Infantile- and Juvenile-Onset Hypophosphatasia (HPP)October 23, 2015 3:48 PM FDA Approves Alexion's (ALXN) Strensiq to Treat Perinatal, Infantile and Juvenile-Onset HPPOctober 23, 2015 3:40 PM Alexion Pharma (ALXN) halted with news pendingOctober 23, 2015 3:38 PM